GlassScriptPhysician profile
Reema N Patel
NPI 1417194085
$10,124.62
in general payments reported to CMS, 2019-2025
28 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,885 · 2022: $1,939 · 2023: $2,299 · 2024: $1,906 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,236 · Education: $64.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,236.28 |
| Education | $64.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,691.24 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,025.25 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $884.19 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $795.26 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $657.71 | 2021-2025 | |
| Leo Pharma INC. | $481.43 | 2021-2023 | Adbry |
| Allergan, INC. | $369.70 | 2021-2022 | |
| Pfizer INC. | $349.98 | 2021-2024 | |
| Galderma Laboratories, L.P. | $342.40 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $342.12 | 2021-2023 | Absorica Ld, Winlevi, Blu-U |
| Ucb, INC. | $332.66 | 2021-2024 | Bimzelx |
| Amgen INC. | $325.21 | 2022-2023 | Otezla |
| Incyte Corporation | $309.88 | 2021-2025 | Opzelura |
| Organon LLC | $218.99 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $176.36 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $158.25 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $128.88 | 2021 | |
| Revance Therapeutics, INC. | $113.23 | 2024-2025 | Daxxify, Daxi |
| Dermavant Sciences, INC. | $86.57 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $82.06 | 2021-2022 | |
| Biofrontera INC. | $51.81 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Merz North America, INC. | $49.00 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.82 | 2024-2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $24.62 | 2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.12 | 2021 | |
| Almirall LLC | $20.24 | 2021 | |
| Mayne Pharma Commercial LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.